Healthcare Industry News: Questcor Pharmaceuticals
News Release - November 3, 2017
Symic Bio Appoints Wayne Froland, Ph.D., as Executive Vice President of Technical OperationsDr. Froland brings over 20 years of pharmaceutical industry experience to the company
SAN FRANCISCO, Nov. 3, 2017 -- (Healthcare Sales & Marketing Network) -- Symic Bio, a biopharmaceutical company developing novel matrix-targeting biotherapeutics, announced today the appointment of Wayne Froland, Ph.D., as Executive Vice President of Technical Operations. Dr. Froland has over 20 years of experience in industry primarily focusing on process development in biopharmaceutical manufacturing.
"Symic Bio represents an extraordinary opportunity of bringing a novel class of therapeutics focused on the biology of the extracellular matrix to underserved areas of medical need," commented Dr. Froland. "The Symic Team has already progressed two programs into mid-stage clinical development and I am very excited to join them in accelerating the further development of these novel therapeutics through the commercialization process and into the hands of physicians and their patients."
Dr. Froland was most recently Associate Vice President at Merck & Co., Inc. where he was responsible for biopharmaceutical product development, commercialization and manufacturing strategy. He has previously worked at Calypte Biomedical, Questcor Pharmaceuticals, Bayer Pharmaceuticals and Aerovance. Dr. Froland is the co-inventor on three patents related to synthesis of therapeutic peptides and has authored 20 peer-reviewed publications in the fields of biochemistry and structural biology. He received his Ph.D. in Biochemistry from the University of Minnesota Medical School and conducted post-doctoral research at the Department of Chemistry, University of California, Berkeley.
About Symic Bio
Symic Bio is a biopharmaceutical company developing novel matrix-targeting biotherapeutics, a new category of therapeutics focused on matrix biology. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix. Symic Bio currently has two clinical candidates: SB-030, which is targeting the prevention of peripheral vein graft failure, and SB-061, directed at disease modification and pain management in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system. For additional information please visit the company's website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio or follow on Twitter at www.twitter.com/symicbio.
Source: Symic Bio
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.